tbuckley/cabot-search huggingface dataset:
Patient reported outcomes in older breast cancer survivors.
Authors: Sharon H. Giordano, Kai-Ping Eric Liao, Liang Li, Daria Zorzi, Mariana Chavez-MacGregor, Susan K. Peterson
Journal: Journal of Clinical Oncology (2020)

12072 Background: The majority of breast cancer patients are age 66 years or older at diagnosis, yet little is known about the symptom burden of older breast cancer survivors. Methods: Using the same process as for SEER-Medicare, data from the Texas Cancer Registry (TCR) and Medicare claims were linked. From this TCR-Medicare dataset, patients age 65 years and older at diagnosis, with localized or regional breast cancer, diagnosed in 2012 and 2013, and still alive in 2018 were identified. To assess long-term outcomes, a mailed survey, which included selected questions from the NCI’s PRO-CTCAE question bank, was sent to 4591 eligible patients along with a $10 gift card. Non-responders were sent a follow-up questionnaire at 4-6 weeks and 8-10 weeks after initial mailing. The percentage reporting symptoms, overall and by treatment received, are described. Results: 1594 survivors completed the questionnaire (35% response rate). Median time from diagnosis to survey completion was 67 months. 70% of responders were age 65-74, 26% age 75-84, and 3% age 85+ at diagnosis. 84% were non-Hispanic white, 6% black, and 9% Hispanic. 77% had localized stage disease and 23% had regional disease at diagnosis. 58% had lumpectomy, 36% had mastectomy, and 2% reported no surgery. 77% had ER+ breast cancer. 28% received adjuvant chemotherapy. 48% had Part D claims for adjuvant endocrine therapy. PROs are reported in Table, overall and by use of chemotherapy and endocrine therapy. Conclusions: Older breast cancer survivors, particularly those who were treated with chemotherapy, experience a high symptom burden. [Table: see text]
Urachal adenocarcinoma of bladder: clinical analysis of six cases
Authors: Bo Song, Xin Li, Shaozhong Xian, Peishan Wu
Journal: BMJ (2017)

The clinical and pathological data of 6 patients with urahcal adenocar, cinoma of the bladder admitted in Beijing Luhe Hospital from 1996 to 2016 were analyzed and relevant literature was reviewed. Urachal carcinoma accounted for 0.66% of the bladder cancers admitted at the same period (6/906) and 6/16 of the bladder adenocarcinomas. Painless hematuria was the most common symptom. One patient had extensive metastasis as shown in biopsy and died 6 month after the diagnosis. Two patients underwent partial excision of bladder with no tumor recurrence. One patient underwent partial cystectomy followed by chemotherapy and radiotherapy, recurrence occurred one year later and he then received radical cystectomy. Another 2 patients underwent laparoscopic cystectomy and en bloc resection of umbilical ligament and umbilicus, and no recurrence was found in the follow-up for 6 years and 15 months, respectively. Pathological and immunohistochemistry are essential for the diagnosis of urachal adenocarcinoma. As it is not sensitive to radiotherapy or chemotherapy, surgery is the preferred treatment for patients with early stage diseases. Individual anticancer therapy may be the trend of treatment.


Key words: 
Urinary bladder neoplasms; Adenocarcinoma; Adenocarcinoma, urachus
Treatment patterns in cervical cancer patients initiating systemic therapy.
Authors: Anuj Shah, Nehemiah Kebede, Ruchit Shah, Shelby Corman, Chizoba Nwankwo
Journal: Journal of Clinical Oncology (2020)

e18009 Background: NCCN recommends the use of systemic treatment for advanced cervical cancer patients. However, no study has assessed treatment patterns in this population. This study described real-world treatments patterns among women with cervical cancer newly initiating a systemic therapy. Methods: Cervical cancer patients with ≥2 claims for systemic therapy (i.e., chemo- or immunotherapy) within a 4-week period between June 2014 – October 2018, no claims within 6 months prior to systemic treatment initiation (baseline period), and continuously enrolled within the baseline period and 3 months post therapy initiation were identified from the Optum Clinformatics DataMart database. Patients who had a cervical cancer-related surgery within ±3 months of therapy initiation were excluded to exclude adjuvant use. All claims for the same systemic therapy without a &gt; 90-day gap or new systemic therapy started within 28 days of a previous treatment were considered to be part of the same LOT. Descriptive analysis, stratified for presence of non-cervical cancers during the baseline period, were conducted to identify most common treatments, durations, and use of mono versus combination therapy within each LOT. Results: 1,229 women newly initiated systemic therapy, 357 (29.0%) received LOT2 and 141 (11.5%) had a LOT3. Treatments received within each LOT are described in the table below. The proportion receiving radiation reduced from LOT1 (49.9%) to LOT2 (12.0%). The mean duration of LOT1 and LOT2 were 2.9 and 3.7 months. The proportion of patients receiving monotherapy in LOT1 and LOT2 were 77.8% and 64.1% respectively. Conclusions: The treatment received by patients in this analysis suggested receipt of guideline concordant care. [Table: see text]
Implementing a digital clinical decision support tool for side effects of antipsychotics: a focus group study
Authors: Henshall Catherine, Cipriani Andrea, Ruvolo David, Macdonald Orla, Wolters Leona, Koychev Ivan, 崔轶
Journal: BMJ (2019)

背景
在医学上，算法可以通过结合关于药物不良反应情况的最新证据，来提供治疗决策，这些证据在疗效上具有可比性。在开始治疗时，它们的使用为改善医生-患者共同决策提供了可能。我们设计了一种决策支持工具(DST)，收录了关于抗精神病药物不良反应的最新证据。该工具可以让患者选择某种抗精神病药物常有的、也是他们想避免的不良反应；然后工具会给出一份建议用药和避免用药的清单。


目的
从患者和精神科医生的角度定性地探讨DST的可接受性和实用性。


方法
这项定性研究于2018年在英国牛津的一家精神卫生社区医院进行。4名患者/护理人员和4名精神科医生被招募到2个焦点小组，以探讨他们对该工具的看法。对数据进行主题分析。


结果
研究结果显示，DST对患者和精神科医生具有很高的可接受性和潜在的可用性。与DST相关的主要议题包括处方偏好和实践对不良反应的考虑和意识应用程序的内容、界面和可访问性对临床实践的影响和在决策中的角色。


结论
一项概念验证临床研究将把本研究结果产生的建议纳入到工具的设计中。


临床意义
对于最新的药物不良反应信息，数字DST使其可能作为医生-患者共同决策的基础。该工具将有能力改善精神病药物治疗的依从性，对临床结果和医疗资源都有益处。
Recent progress of vitamin C in management of sepsis
Authors: Shimin Lu, Shan Tian
Journal: BMJ (2018)

Sepsis is frequently associated with multi-system organ dysfunction and refractory hypotension, leading to a high mortality and poor prognosis. As an antioxidant, ascorbic acid (vitamin C) is an important auxiliary factor for many enzymes in the organism. Numerous studies have revealed that vitamin C can attenuate the inflammatory response, improve microcirculatory and hypotension in sepsis, and also can enhance the role of catecholamine in central nervous system, to prevent sepsis-induced organ failure and improve prognosis of patients.


Key words: 
Sepsis; Ascorbic acid; Antioxidants
糜蛋白酶联合碳酸氢钠治疗胃石症效果分析
Authors: 陈鹏, 胡立华, 田琳, 石春林, 张沛怡
Journal: BMJ (2012)

对24例经胃镜证实胃石症患者口服糜蛋白酶20000 U加5％碳酸氢钠50 ml、2次/d,同时口服或静脉滴注奥美拉唑治疗.3d后复查胃镜,如有残石者给予糜蛋白酶80000 U加5％碳酸氢钠200 ml胃石内多点注射及胃石表面喷洒,3d后再复查胃镜,如仍有残石则重复内镜下药物溶石至胃石全部排出.结果全部患者治愈,16例经口服药物溶石成功,6例一次内镜下药物溶石,1例采用2次,1例采用4次.提示糜蛋白酶联合碳酸氢钠治疗胃石症简单易行安全,疗效满意。
Long-term survival rates in cancer patients achieved with metronomic chemotherapy (cyclophosphamide and methotrexate).
Authors: Viacheslav Chubenko, Ludmila Zagorskaya, Valentina Lukyanchikova, Fedor Vladimirovich Moiseenko, Nuriniso Abduloeva, Albina Zhabina, Natalia Levchenko, Mikhail Kramchaninov, Ksenia Shelekhova, Evgenii Zykov, Anna Meldo, Alexey Kudryavcev, Elena Napolskaya, Vladimir Moiseyenko
Journal: Journal of Clinical Oncology (2020)

e15519 Background: Metronomic therapy (MT) is one of the most promising advances in cancer treatment strategy focused on both tumor cells and their microenvironment, specifically anti-angiogenic, immune and metabolic regulation. The treatment modality is a durable cytostatic drugs exposure with less toxicity. We investigated the efficacy of MT in point of prolonged duration of response (more than 6 months) in pts with the advanced resistant tumors. Methods: A total of 678 pts have been enrolled in the study and have been treated MT cyclophosphamide 50 mg (qd, PO) and methotrexate 2.5 mg (BID, PO) twice per week dosing schedule until progression. 508 pts (75%) had disease progression during first 6 months. Long-term efficacy (more than 6 months) was assessed in 170 pts (25%). The study population characteristics were female 122 (72%) vs male 48 (28%). Among the enrolled pts median age was 70 years (range from 37 to 91 years). ECOG status ranged from 0 to 4 (median - 1). The majority of pts received MT as a 2nd and 3rd line (57%) of the therapy (range from 1 to 11): 1-2 – 106 (62%), 3-4 - 52 (31%), 5 and more - 12 (7%). The distribution of pts by diagnosis is presented in the table 1. The majority of MT pts were represented by advanced clinical stage III-IV (97,6%): I - 1 (0,5%), II - 3 (2%), III - 7 (4%), IV - 159 (93,5%). MT commonly used in early-stages cancer in elderly patients with multiple comorbidities contraindicated to standard treatment. Most pts had two or multiple metastatic sites. Results: The ongoing long-term effect for MT indication was from 6 to 46 months. The main group consisted of the breast and colorectal cancer, 27% and 15%, respectively. The median time to progression was 9 months (16 months in CR was achieved (0,4%), 11 months and 9 months with a partial response (3,4%) and stable disease (21,2%), respectively). 12 (1,7%) pts are on ongoing long-term follow up more than 24 months. MT was well-tolerated. Drug related adverse events were described upon the study: hematological (10,2%, Gr 3-4 – 3,5%) vs non-hematological (6,6%, Gr 3-4 1,7%) toxicity. Conclusions: MT schedule demonstrated effectiveness in patients with advanced resistant tumors. The median duration of the effectiveness doesn’t depend on the line of therapy, tumor localization and objective response. The role of possible predictive markers of clinical benefit is question of further trials. [Table: see text]
群组管理糖耐量减低患者的效果分析
Authors: 陈亮, 魏靖, 杨竹洁, 王林娣, 陈文, 许丽霞
Journal: BMJ (2012)

将120例糖耐量减低患者以抽签法分为对照组和干预组.对照组接受常规管理；干预组接受群组管理,即按BMI将患者分成3组,对患者的自我管理能力进行干预,并每月进行一次由医生、护士、志愿者、患者共同参加的集体干预活动.1年后,干预组糖尿病的发生显著低于对照组(2例与5例),糖耐量正常者明显增加(4例与1例),自我管理方面均有明显改善。
Clinical analysis of two cases of pulmonary alveolar proteinosis and literature review
Authors: Yijuan Huang, Yafang Lou, Xuchun Ding, Yajie Shi
Journal: BMJ (2014)

Two cases of pulmonary alveolar proteinosis were reported with a literature review. The epidemiologic, clinical and diagnostic aspects of pulmonary alveolar proteinosis were discussed. The common clinical symptom was progressive dyspnea, cough and expectoration. And its typical finding of computed tomography was pulmonary infiltration with map or paving stone sign. A definite diagnosis was made by lung biopsy and PAS dyeing. Timely diagnosis and whole lung lavage are essential.


Key words: 
Pulmonary alveolar proteinosis; Bronchoalveolar lavage
Comparison of characteristics and outcomes among veterans receiving first-line immunotherapy versus chemotherapy for stage IV non-small cell lung cancer.
Authors: Christina D Williams, Lin Gu, Vishal Vashistha, Ashlyn Press, Michael J. Kelley
Journal: Journal of Clinical Oncology (2020)

e19295 Background: Immunotherapy (IO) has revolutionized the treatment paradigm for patients with advanced non-small cell lung cancer (NSCLC). Study objectives were to evaluate utilization of IO as first-line (1L) therapy and compare clinical characteristics between patients receiving IO and those receiving CT in 1L setting. Methods: Using the U.S. Department of Veterans Affairs corporate data warehouse, patients with stage IV NSCLC diagnosed 2012-2017 and initiated non-targeted systemic therapy within 120 days of diagnosis were selected. Unadjusted descriptive statistics were used to compare patient characteristics, inpatient and outpatient clinic visits, and prevalence of select adverse events (AE) between patients receiving IO monotherapy and CT. Kaplan-Meier and Cox regression approaches with and without propensity score matching (PSM) were used for overall survival (OS) analyses. OS was calculated from treatment initiation date to death or end of study period in June 2019. Results: 4609 patients were included in the analysis: 3.4% (n = 156) received IO monotherapy, 96% (n = 4426) received CT, and 0.6% (n = 27) received IO+CT (IO+CT not included in analysis). IO patients were older than CT patients (median age 69 vs. 66 years, p &lt; 0.0001) and more frequently resided in the Midwest and West regions whereas CT patients were more likely to live in the Northeast and South (p = 0.0024). There were no significant differences in IO and CT by other demographic and clinical characteristics. Estimated median OS was 7.5 months (95% CI 7.2-7.7) for CT and 7.9 months (95% CI 5.3-12.6) for IO patients. The unadjusted HR for IO compared to CT patients was 0.81 (95% CI 0.67-0.98). With 1:4 PSM (144 and 559 patients matched in the IO and CT groups, respectively), the HR was 0.75 (95% CI 0.60-0.93). The mean number of outpatient visits for IO and CT patients were 47 and 36, respectively (p = 0.003). No difference in number of hospitalizations or length of hospital stays between the two groups was observed. Common AEs in the IO group were dyspnea (58%), colitis/enterocolitis (42%), and anemia (30%). Common AEs among CT patients were colitis/enterocolitis (36%), anemia (32%), and nausea/vomiting (31%). Conclusions: In a real-world 1L setting among veterans with NSCLC, improvement in OS was observed among patients receiving IO monotherapy compared to those receiving CT, and IO patients had a greater number of outpatient visits. Continued assessment of treatment patterns and impact of IO are needed as the use of IO continues to expand.
Medical and gastroenterological education during the COVID-19 outbreak
Authors: Brigida Barberio, Davide Massimi, Anna Dipace, Fabiana Zingone, Fabio Farinati, Edoardo V. Savarino
Journal: Nature Reviews Gastroenterology & Hepatology (2020)

The outbreak of coronavirus disease 2019 has undeniably affected modalities of medical and gastroenterology training in all endemic areas. Indeed, the adoption of various distance-learning techniques has been mandatory to facilitate education and enhance skills such as problem-solving, self-directed learning, open communication and also holistic non-cognitive attributes such as adaptability and collaboration.
Survey on the rationality and standardization of clinical oxygen therapy in a general hospital in Shanghai
Authors: Yijun Zhu, Cihang Zhou, Yiping Han
Journal: BMJ (2020)

Objective
To survey the current status of oxygen therapy in a comprehensive hospital in Shanghai and to assess its rationality and standardization.


Methods
Cluster sampling method was adopted in selecting in-patients who received oxygen therapy from various departments in Changhai Hospital from March 2018 to June 2018. General information such as gender, age, and department were recorded. The self-developed Oxygen Therapy Form for Inpatients was used to collect clinical data such as admission diagnosis, oxygen therapy indications, oxygen therapy orders, and related parameters. BTS guideline for Oxygen use in adults in Health care and Emergency Settings was used to assess the rationality and standardization of oxygen therapy.


Results
In this survey, 464 patients were assessed for their oxygen treatment orders. According to the guidelines, the overall reasonable rate of oxygen therapy was 92.2% (428/464); the standardization rate of oxygen therapy was 22.4% (104/464). Among them, the reasonable rate of oxygen therapy in internal medicine ward (64.7%, 46/71) was lower than that in surgery ward (98.3%, 304/309) and in wards of other specialties (92.8%, 78/84) (χ2=91.09, P<0.01); while the reasonable rate of general ward (90.9%, 362/398) was lower than that of ICU (100.0%, 66/66) (χ2=6.47, P<0.05). In the standardization assessment, the wards of other specialties (54.8%, 46/84) were better than the internal medicine ward (26.8%, 19/71) and the surgery ward (12.6%, 39/309) (χ2=68.35, P<0.01); while the ICU (65.2%, 43/66) was superior to the general ward (15.3%, 61/398) (χ2=80.81, P<0.01).


Conclusions
The rationality of oxygen therapy in the general hospital is acceptable, but the standardization needs to be improved. There are some differences in the rationality and standardization of oxygen therapy orders among different departments and different levels of wards.


Key words: 
Oxygen inhalation therapy; Cross-sectional studies; Clinical audit
Cost-effectiveness of various maintenance therapies based on mutation status following first-line treatment of primary epithelial ovarian cancer in the United States.
Authors: Courtney Penn, Melissa Wong, Christine S. Walsh
Journal: Journal of Clinical Oncology (2020)

e19399 Background: The recent SOLO1, PRIMA, and PAOLA trials all reported positive efficacy results, making it difficult to determine optimal upfront maintenance therapy for patients with primary, advanced ovarian cancer. We evaluated the cost-effectiveness of the maintenance strategies outlined in these trials for BRCA-positive patients, homologous-recombination deficient patients without a BRCA mutation (HRD-positive), and homologous-recombination proficient (HRD-negative) patients. Methods: Three decision analysis models were developed, one for each mutation status. We evaluated olaparib (SOLO1), olaparib/bevacizumab (PAOLA), bevacizumab alone (PAOLA), and niraparib (PRIMA) maintenance strategies. Base case 1 assessed olaparib vs olaparib/bevacizumab vs bevacizumab vs niraparib vs no maintenance therapy in BRCA-positive patients. Base cases 2 and 3 assessed olaparib/bevacizumab vs bevacizumab vs niraparib vs no maintenance therapy in HRD-positive and HRD-negative patients, respectively. Time horizon was 24 months. Costs, measured in U.S. dollars, were estimated from Medicare claims, wholesale acquisition prices, and previously published sources. Incremental cost-effectiveness ratios (ICERs) were in dollars per progression-free life-year saved (PF-LYS). One-way sensitivity analyses were performed varying drug cost and progression-free survival. Results: Assuming a willingness-to-pay threshold of $100,000/PF-LYS, none of the drug maintenance strategies could be considered cost effective compared with observation. In BRCA-positive patients (base case 1), olaparib monotherapy was the most cost-effective strategy, yielding an ICER of $181,059/PF-LYS. The third-party payer cost per 28-day supply of olaparib would need to be reduced from approximately $17,000 to $9,200 to be considered cost effective compared with observation. In HRD-positive patients (base case 2) and HRD-negative patients (base case 3), bevacizumab monotherapy was the most cost-effective option, with ICERs of $326,491/PF-LYS and $253,937/PF-LYS respectively. Conclusions: At current costs, maintenance therapy for primary ovarian cancer is not cost effective, regardless of mutation status. In BRCA-positive women, lowering the cost of olaparib may make it cost effective compared with observation.
Aspirin for prevention of the venous thromboembolism: a meta-analysis
Authors: Jingwen Fan, Jie Zhu
Journal: BMJ (2019)

Objective
To systematically review the efficacy and safety of aspirin in prevention of venous thromboembolism (VTE) compared to LMWH, warfarin, rivaroxaban and placebo.


Methods
Randomized controlled trials (RCT) and cohort studies comparing aspirin to LMWH, warfarin, rivaroxaban and placebo for prevention of VTE were retrieved from PubMed, Embase, Cochrane Library, Scopus, Ovid, CINAHL and Wanfang Data. Meta-analysis was performed by using Rev Man 5.3 software after data extraction and quality evaluation.


Results
Totally 40 studies were included. There were no significant differences in overall rate of VTE (RR=1.08, 95%CI: 0.97-1.20, P=0.15) , major bleeding incidence (RR=0.97, 95%CI: 0.81-1.16, P=0.73) and death (RR=0.86, 95%CI: 0.71-1.03, P=0.10) between aspirin and LMWH groups. Aspirin was associated with a lower risk of VTE (RR=0.49, 95%CI: 0.43-0.57, P<0.05) , major bleeding (RR=0.62, 95%CI: 0.46-0.84, P<0.01) and death (RR=0.32, 95%CI: 0.15-0.64, P<0.01) compared with warfarin. Rivaroxaban was associated with a significantly lower risk of deep-vein thrombosis (DVT) (RR=2.55, 95%CI: 1.41-4.62, P<0.01) , while no significant differences in pulmonary embolism (PE) (RR=1.86, 95%CI: 0.69-5.04, P=0.22) , major bleeding (RR=0.90, 95%CI: 0.44-1.87, P=0.79) and death (RR=1.50, 95%CI: 0.60-3.74, P=0.39) compared with aspirin. Compared to placebo group aspirin significantly reduced the risk for VTE (RR=0.81, 95%CI: 0.72-0.90, P<0.01) , increased the frequency of major bleeding (RR=1.17, 95%CI: 1.06-1.30, P<0.01) , while there was no significant difference in death between aspirin and placebo (RR=0.97, 95%CI: 0.89-1.04, P=0.38) .


Conclusion
Aspirin is not inferior to LMWH, warfarin, and rivaroxaban in safety and efficiency for preventing VTE, and can be used for VTE prevention for patients after total joint arthroplasty.


Key words: 
Venous thromboembolism; Aspirin; Prevention; Major bleeding; All-cause mortality; Meta-analysis
嗜酸粒细胞性支气管炎的诊断与治疗
Authors: 苏楠
Journal: BMJ (2009)

1989年Gibson等[1]描述了一组患者的特征:慢性咳嗽(病程超过3周),无痰或晨咳少许黏痰,无哮喘、呼吸困难、咯血、胸膜炎等病史,肺功能正常,峰流速(PEF)变异率正常,乙酰甲胆碱激发试验阴性(有部分患者处于正常范围的高值),支气管舒张试验阴性,痰中嗜酸粒细胞(Eos)计数明显增高(11.5%～85.9%),吸入二丙酸倍氯米松(beclomethasone 400μg,2 次/d)2周后咳嗽完全消失.当时认为这些患者不符合哮喘的诊断,也不符合当时的任何一个呼吸道疾病类型,因此提出了嗜酸粒细胞性支气管炎(eosinophilic bronchitis,EB)的诊断。
Do patients of multiple sclerosis need to be treated as early as possible? LI Hai-feng
Authors: 李海峰
Journal: BMJ (2008)

多发性硬化(multiple sclerosis,MS)是中枢神经系统炎性脱髓鞘疾病,临床表现为复发缓解和功能障碍进展.患者早期可表现为孤立的脱髓鞘事件发作,称作临床孤立综合征(clinically isolated syndrome,CIS)。
HOGG1 polymorphism and gastric cancer/atrophic gastritis
Authors: J. Cheng, L. Sun
Journal: Journal of Clinical Oncology (2009)

e15535 Objective: 8-Hydroxydeoxyguanine (8-OHdG) formation is one of the most common types of oxidative DNA damage leading to gastric cancer development and human oxoguanine glycosylase 1(hOGG1) is responsible for repairing 8-OHdG lesions. Among several hOGG1 gene polymorphisms, the Ser→Cys polymorphism at position 326 is related to decreased repair function. We aimed to investigate the association between Ser326Cys hOGG1 polymorphism and gastric cancer/atrophic gastritis. Methods: 488 subjects (73 with gastric cancer, 160 with atrophic gastritis and 255 controls) were prospectively enrolled from 2005 to 2008 in Sir Run Run Shaw Hospital. Genomic DNA was obtained from peripheral blood and PCR-RFLP analysis was performed to distinguish the genotyping of hOGG1 Ser326Cys polymorphism. Statistical analysis was conducted by two-sample t-test or generalized regression models for continuous variables and the Pearson χ 2 test for categorical variables. Logistic regression models were fitted to find the risk factors for gastric cancer and atrophic gastritis. For all analyses, significance was determined at the P &lt; 0.05 level (two-tailed). Results: Patients with gastric cancer were significantly older than the control group (59.6±11.2yrs vs 43.6±10.3 yrs, P&lt;0.0001) and atrophic gastritis group (59.6±11.2yrs vs 51.4±10.6 yrs, P&lt;0.0001). Gastric cancer group had significantly higher rate of male than atrophic gastritis group (65.8% vs 48.7% in atrophic gastritis, p=0.02). Neither the hOGG1 Ser/Cys nor the Cys/Cys genotype was associated with gastric cancer, compared with the Ser/Ser genotype (OR: 0.96, 95% CI (0.51–1.84) and OR: 1.1, 95% CI: (0.48–2.1)). Ser/Cys and Cys/Cys were significantly associated with atrophic gastritis (OR: 1.76, 95% CI: 1.03–3.0) and OR: 2.38, 95%CI: 1.34–4.23)). After controlling for age, gender, smoking and alcohol, these significant associations still held with OR: 2.05, 95% CI: (1.14–3.68) for Ser/Cys and OR: 2.76, 95% CI: (1.47–5.18) for Cys/Cys. Conclusions: Our study supported that hOGG1 polymorphisms (genotype Ser/Cys and Cys/Cys) are associated with atrophic gastritis. These associations still exist after controlling for age, gender, smoking and alcohol. No significant association was detected between hOGG1 polymorphisms (genotype Cys/Cys or Ser/Cys) and gastric cancer. No significant financial relationships to disclose.